Published in Ann Neurol on December 01, 2002
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med (2007) 5.25
Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A (2005) 3.52
Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol (2003) 3.25
Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci U S A (2003) 2.66
Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One (2007) 2.41
Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle (2011) 2.41
Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci U S A (2008) 2.31
Lack of myostatin results in excessive muscle growth but impaired force generation. Proc Natl Acad Sci U S A (2007) 2.25
Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med (2009) 2.21
Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem (2008) 2.11
Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2006) 1.97
Muscle regeneration in the prolonged absence of myostatin. Proc Natl Acad Sci U S A (2005) 1.81
Contractile properties of EDL and soleus muscles of myostatin-deficient mice. J Appl Physiol (1985) (2006) 1.81
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A (2008) 1.80
Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol (1985) (2010) 1.76
Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J (2011) 1.67
Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol (2006) 1.64
Tendons of myostatin-deficient mice are small, brittle, and hypocellular. Proc Natl Acad Sci U S A (2007) 1.57
Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity. Proc Natl Acad Sci U S A (2009) 1.55
Cellular mechanisms of tissue fibrosis. 4. Structural and functional consequences of skeletal muscle fibrosis. Am J Physiol Cell Physiol (2013) 1.41
Myostatin does not regulate cardiac hypertrophy or fibrosis. Neuromuscul Disord (2007) 1.40
Transgenic expression of {alpha}7{beta}1 integrin maintains muscle integrity, increases regenerative capacity, promotes hypertrophy, and reduces cardiomyopathy in dystrophic mice. Am J Pathol (2005) 1.37
Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve (2009) 1.34
A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy. Sci Transl Med (2010) 1.33
Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Hum Mol Genet (2008) 1.32
Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech (2015) 1.30
Role of TGF-β signaling in inherited and acquired myopathies. Skelet Muscle (2011) 1.28
Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome (2012) 1.28
Targeting fibrosis in Duchenne muscular dystrophy. J Neuropathol Exp Neurol (2010) 1.27
Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta (2006) 1.25
A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther (2014) 1.22
Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum Gene Ther (2009) 1.21
Clinical, agricultural, and evolutionary biology of myostatin: a comparative review. Endocr Rev (2008) 1.18
Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal (2009) 1.16
Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J Biol Chem (2010) 1.16
Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality. Am J Pathol (2005) 1.15
Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. Am J Pathol (2005) 1.10
Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. PLoS One (2010) 1.10
Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury. J Trauma (2010) 1.10
Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Hum Mol Genet (2009) 1.09
Follistatin improves skeletal muscle healing after injury and disease through an interaction with muscle regeneration, angiogenesis, and fibrosis. Am J Pathol (2011) 1.07
Wasting mechanisms in muscular dystrophy. Int J Biochem Cell Biol (2013) 1.07
Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. Muscle Nerve (2010) 1.03
Inhibition of activin receptor type IIB increases strength and lifespan in myotubularin-deficient mice. Am J Pathol (2011) 1.03
Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am J Physiol Heart Circ Physiol (2011) 1.03
Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants. J Neurol Neurosurg Psychiatry (2014) 1.00
Therapeutics in duchenne muscular dystrophy. NeuroRx (2006) 0.98
Regenerative pharmacology in the treatment of genetic diseases: the paradigm of muscular dystrophy. Int J Biochem Cell Biol (2008) 0.98
Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol (2011) 0.98
Targeted mutations in myostatin by zinc-finger nucleases result in double-muscled phenotype in Meishan pigs. Sci Rep (2015) 0.97
Myotonic dystrophy: therapeutic strategies for the future. Neurotherapeutics (2008) 0.96
Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A. Am J Pathol (2007) 0.96
Overload-induced skeletal muscle extracellular matrix remodelling and myofibre growth in mice lacking IL-6. Acta Physiol (Oxf) (2009) 0.95
Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice. Am J Pathol (2010) 0.94
A Wnt-TGFβ2 axis induces a fibrogenic program in muscle stem cells from dystrophic mice. Sci Transl Med (2014) 0.92
Endurance exercise training in myostatin null mice. Muscle Nerve (2010) 0.92
Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice. Am J Pathol (2009) 0.92
Cytokines and chemokines as regulators of skeletal muscle inflammation: presenting the case of Duchenne muscular dystrophy. Mediators Inflamm (2013) 0.91
Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction. Am J Physiol Regul Integr Comp Physiol (2009) 0.90
Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis. PLoS One (2008) 0.90
Approaching a new age in Duchenne muscular dystrophy treatment. Neurotherapeutics (2008) 0.88
Myogenic Akt signaling attenuates muscular degeneration, promotes myofiber regeneration and improves muscle function in dystrophin-deficient mdx mice. Hum Mol Genet (2011) 0.88
Concise Review: Epigenetic Regulation of Myogenesis in Health and Disease. Stem Cells Transl Med (2016) 0.88
Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials. ILAR J (2014) 0.88
Therapeutic developments in spinal muscular atrophy. Ther Adv Neurol Disord (2010) 0.87
Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice. Acta Myol (2008) 0.87
Myostatin is upregulated following stress in an Erk-dependent manner and negatively regulates cardiomyocyte growth in culture and in a mouse model. PLoS One (2010) 0.87
A protein with similarity to PTEN regulates aggregation territory size by decreasing cyclic AMP pulse size during Dictyostelium discoideum development. Eukaryot Cell (2008) 0.87
Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-beta and CTGF/CCN2. J Cell Commun Signal (2008) 0.87
Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy. Hum Mol Genet (2015) 0.87
Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function. Neuromuscul Disord (2014) 0.86
Runx1 Transcription Factor Is Required for Myoblasts Proliferation during Muscle Regeneration. PLoS Genet (2015) 0.86
Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy. Ther Adv Neurol Disord (2013) 0.86
Ubiquitous Gasp1 overexpression in mice leads mainly to a hypermuscular phenotype. BMC Genomics (2012) 0.85
Long-term systemic myostatin inhibition via liver-targeted gene transfer in golden retriever muscular dystrophy. Hum Gene Ther (2011) 0.85
Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibition. Dis Model Mech (2014) 0.85
Genetic myostatin decrease in the golden retriever muscular dystrophy model does not significantly affect the ubiquitin proteasome system despite enhancing the severity of disease. Am J Transl Res (2013) 0.84
Cytotoxic aggregation and amyloid formation by the myostatin precursor protein. PLoS One (2010) 0.83
Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy. Nucleic Acids Res (2014) 0.81
Translating mighty mice into neuromuscular therapeutics: is bigger muscle better? Am J Pathol (2006) 0.80
Changes in skeletal muscle and tendon structure and function following genetic inactivation of myostatin in rats. J Physiol (2015) 0.80
Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials. Am J Transl Res (2016) 0.80
Latent myostatin has significant activity and this activity is controlled more efficiently by WFIKKN1 than by WFIKKN2. FEBS J (2013) 0.80
Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor. Mol Ther Nucleic Acids (2014) 0.79
Myostatin in the pathophysiology of skeletal muscle. Curr Genomics (2007) 0.78
A high-content, high-throughput siRNA screen identifies cyclin D2 as a potent regulator of muscle progenitor cell fusion and a target to enhance muscle regeneration. Hum Mol Genet (2013) 0.77
The quasi-parallel lives of satellite cells and atrophying muscle. Front Aging Neurosci (2015) 0.77
Could gene therapy be the future for muscular dystrophy? Therapy (2010) 0.77
Genetic disruption of Smad7 impairs skeletal muscle growth and regeneration. J Physiol (2015) 0.77
Administration of a soluble activin type IIB receptor promotes the transplantation of human myoblasts in dystrophic mice. Cell Transplant (2012) 0.77
The FVB Background Does Not Dramatically Alter the Dystrophic Phenotype of Mdx Mice. PLoS Curr (2015) 0.77
Role of IGF-I in follistatin-induced skeletal muscle hypertrophy. Am J Physiol Endocrinol Metab (2015) 0.76
Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ. PLoS Genet (2016) 0.76
AAV2-mediated follistatin overexpression induces ovine primary myoblasts proliferation. BMC Biotechnol (2014) 0.76
Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures. Skelet Muscle (2016) 0.76
Characterisation of connective tissue from the hypertrophic skeletal muscle of myostatin null mice. J Anat (2012) 0.76
Deletion of Galgt2 (B4Galnt2) Reduces Muscle Growth in Response to Acute Injury and Increases Muscle Inflammation and Pathology in Dystrophin-Deficient Mice. Am J Pathol (2015) 0.76
Treatment with rGDF11 does not improve the dystrophic muscle pathology of mdx mice. Skelet Muscle (2016) 0.76
The C313Y Piedmontese mutation decreases myostatin covalent dimerisation and stability. BMC Res Notes (2011) 0.75
Erythropoietin reduces the expression of myostatin in mdx dystrophic mice. Braz J Med Biol Res (2014) 0.75
Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med (2004) 7.80
Induction of cachexia in mice by systemically administered myostatin. Science (2002) 4.39
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev (2012) 4.19
Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest (2002) 3.28
Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci U S A (2003) 2.66
Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS One (2009) 1.98
Redundancy of myostatin and growth/differentiation factor 11 function. BMC Dev Biol (2009) 1.56
BMP9 and BMP10 are critical for postnatal retinal vascular remodeling. Blood (2012) 1.53
Regulation of metanephric kidney development by growth/differentiation factor 11. Dev Biol (2003) 1.42
Teaching NeuroImages: Reversible splenial cytotoxic edema in acute mountain sickness. Neurology (2011) 1.39
The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding. EMBO J (2009) 1.33
The Caenorhabditis elegans AMP-activated protein kinase AAK-2 is phosphorylated by LKB1 and is required for resistance to oxidative stress and for normal motility and foraging behavior. J Biol Chem (2008) 1.19
Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation. J Physiol (2012) 1.16
Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. J Exp Med (2011) 1.10
Secreted VAPB/ALS8 major sperm protein domains modulate mitochondrial localization and morphology via growth cone guidance receptors. Dev Cell (2012) 1.05
Evaluation of reliability of traditional and computerized neurobehavioral tests. Neurotoxicology (2006) 1.03
Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. Muscle Nerve (2010) 1.03
Expression and function of myostatin in obesity, diabetes, and exercise adaptation. Med Sci Sports Exerc (2011) 1.03
Influence of a municipal solid waste incinerator on ambient air and soil PCDD/Fs levels. Chemosphere (2006) 1.02
Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation. Blood (2013) 1.01
Regulation of GDF-11 and myostatin activity by GASP-1 and GASP-2. Proc Natl Acad Sci U S A (2013) 0.99
Myostatin inhibition prevents diabetes and hyperphagia in a mouse model of lipodystrophy. Diabetes (2012) 0.98
Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression. Proc Natl Acad Sci U S A (2013) 0.96
Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury. Circulation (2009) 0.95
Endurance exercise training in myostatin null mice. Muscle Nerve (2010) 0.92
Growth differentiation factor 11 signaling controls retinoic acid activity for axial vertebral development. Dev Biol (2010) 0.89
Mechanisms involved in the enhancement of mammalian target of rapamycin signalling and hypertrophy in skeletal muscle of myostatin-deficient mice. FEBS Lett (2010) 0.89
Chronic myopathy due to immunoglobulin light chain amyloidosis. Mol Genet Metab (2013) 0.88
Deleted in cancer 1 (DICE1) is an essential protein controlling the topology of the inner mitochondrial membrane in C. elegans. Development (2006) 0.88
The efficiency of RNA interference in Bursaphelenchus xylophilus. Mol Cells (2008) 0.87
Concentrations of polybrominated diphenyl ethers, polychlorinated dibenzo-p-dioxins and dibenzofurans, and polychlorinated biphenyls in human blood samples from Korea. Sci Total Environ (2005) 0.86
Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibition. Dis Model Mech (2014) 0.85
Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients. Seizure (2012) 0.84
Opioid sparing effect of low dose ketamine in patients with intravenous patient-controlled analgesia using fentanyl after lumbar spinal fusion surgery. Korean J Anesthesiol (2013) 0.83
Assessment of the spatial distribution of coplanar PCBs, PCNs, and PBDEs in a multi-industry region of South Korea using passive air samplers. Environ Sci Technol (2008) 0.82
Erythropoietin contributes to slow oxidative muscle fiber specification via PGC-1α and AMPK activation. Int J Biochem Cell Biol (2013) 0.82
Cardiac myocyte-specific ablation of follistatin-like 3 attenuates stress-induced myocardial hypertrophy. J Biol Chem (2011) 0.82
Physical and functional interactions of Caenorhabditis elegans WRN-1 helicase with RPA-1. Biochemistry (2012) 0.81
Congener-specific approach to human PCB concentrations by serum analysis. Chemosphere (2007) 0.80
Pinched inlet split flow thin fractionation for continuous particle fractionation: application to marine sediments for size-dependent analysis of PCDD/Fs and metals. Anal Chem (2004) 0.79
Pinched inlet gravitational split-flow thin fractionation of airborne particles and analysis of size dependent level of PCDD/Fs. J Sep Sci (2005) 0.78
Zfp423/OAZ mutation reveals the importance of Olf/EBF transcription activity in olfactory neuronal maturation. J Neurosci (2012) 0.78
A case study of dioxin monitoring in and around an industrial waste incinerator in Korea. Chemosphere (2005) 0.77
Administration of a soluble activin type IIB receptor promotes the transplantation of human myoblasts in dystrophic mice. Cell Transplant (2012) 0.77
Speed and endurance: you can have it all. J Appl Physiol (1985) (2010) 0.76
The analgesic effect of ultrasound-guided transverse abdominis plane block after laparoscopic totally extraperitoneal hernia repair. Korean J Anesthesiol (2012) 0.75
Suppressing effect of goethite on PCDD/F and HCB emissions from plastic materials incineration. Chemosphere (2007) 0.75
Factors contributing to driving by people with uncontrolled seizures. Seizure (2011) 0.75
Characteristics and emission factors of PCDD/Fs in various industrial wastes in South Korea. Chemosphere (2009) 0.75